Publication:
Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malaria

dc.contributor.authorJoel Tarningen_US
dc.contributor.authorMarcus J. Rijkenen_US
dc.contributor.authorRose McGreadyen_US
dc.contributor.authorAung Pyae Phyoen_US
dc.contributor.authorWarunee Hanpithakpongen_US
dc.contributor.authorNicholas P J Dayen_US
dc.contributor.authorNicholas J. Whiteen_US
dc.contributor.authorFrançois Nostenen_US
dc.contributor.authorNiklas Lindegardhen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherNuffield Department of Clinical Medicineen_US
dc.contributor.otherShoklo Malaria Research Uniten_US
dc.date.accessioned2018-06-11T05:13:49Z
dc.date.available2018-06-11T05:13:49Z
dc.date.issued2012-04-01en_US
dc.description.abstractPregnant women are particularly vulnerable to malaria. The pharmacokinetic properties of antimalarial drugs are often affected by pregnancy, resulting in lower drug concentrations and a consequently higher risk of treatment failure. The objective of this study was to evaluate the population pharmacokinetic properties of piperaquine and dihydroartemisinin in pregnant and nonpregnant women with uncomplicated malaria. Twenty-four pregnant and 24 matched nonpregnant women on the Thai-Myanmar boarder were treated with a standard fixed oral 3-day treatment, and venous plasma concentrations of both drugs were measured frequently for pharmacokinetic evaluation. Population pharmacokinetics were evaluated with nonlinear mixed-effects modeling. The main pharmacokinetic finding was an unaltered total exposure to piperaquine but reduced exposure to dihydroartemisinin in pregnant compared to nonpregnant women with uncomplicated malaria. Piperaquine was best described by a three-compartment disposition model with a 45% higher elimination clearance and a 47% increase in relative bioavailability in pregnant women compared with nonpregnant women. The resulting net effect of pregnancy was an unaltered total exposure to piperaquine but a shorter terminal elimination half-life. Dihydroartemisinin was best described by a one-compartment disposition model with a 38% lower relative bioavailability in pregnant women than nonpregnant women. The resulting net effect of pregnancy was a decreased total exposure to dihydroartemisinin. The shorter terminal elimination half-life of piperaquine and lower exposure to dihydroartemisinin will shorten the posttreatment prophylactic effect and might affect cure rates. The clinical impact of these pharmacokinetic findings in pregnant women with uncomplicated malaria needs to be evaluated in larger series. Copyright © 2012, American Society for Microbiology. All Rights Reserved.en_US
dc.identifier.citationAntimicrobial Agents and Chemotherapy. Vol.56, No.4 (2012), 1997-2007en_US
dc.identifier.doi10.1128/AAC.05756-11en_US
dc.identifier.issn10986596en_US
dc.identifier.issn00664804en_US
dc.identifier.other2-s2.0-84858669751en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/14880
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84858669751&origin=inwarden_US
dc.subjectMedicineen_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titlePopulation pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malariaen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84858669751&origin=inwarden_US

Files

Collections